# Organic Solvent Nanofiltration (OSN) & Membrane Separation in API Purification & Solvent Exchange

# Cross-Flow Permeate Flux Dynamics, MWCO Selectivity, Concentration Polarization, and Non-Thermal Solvent Swaps

Traditional pharmaceutical batch operations rely heavily on vacuum distillation for solvent exchange (e.g., swapping Tetrahydrofuran to Ethanol prior to crystallization) and active ingredient concentration. However, repeated thermal distillations consume vast amounts of utility steam, create boiling hot-spots that degrade sensitive moieties, and leave stubborn residual traces of high-boiling solvents.

Organic Solvent Nanofiltration (OSN), also designated Solvent Resistant Nanofiltration (SRNF), enables molecular-scale separations directly in harsh organic solvents (THF, DMF, DCM, Toluene, Acetone) without phase transitions, operating under hydraulic driving pressures ($20 - 60\text{ bar}$).

# 1. Separation Mechanics: Molecular Weight Cut-Off (MWCO)

OSN membranes operate in the pressure-driven nanofiltration realm ($0.5 - 2.0\text{ nm}$ pore dimensions), discriminating solutes based on steric size, hydrodynamic volume, and shape:

                       MEMBRANE SEPARATION SPECTRUM (PORE SIZE)
   Reverse Osmosis (< 150 Da)    OSN Nanofiltration (200 - 1,000 Da)   Ultrafiltration (2k - 100k Da)
  ◄───────────────┼──────────────────────────────┼──────────────────────────────►
   Water Desalination &          Target API Active Concentration        Protein & Biologics
   Small Organics Retention      & Homogeneous Catalyst Recovery        Concentration

# 1.1. Solute Rejection ($R_i$)

The rejection of solute $i$ is defined as:

• Target API Active ($MW \approx 450 - 900\text{ Da}$): Retained with $R_{API} > 99.5\%$.
• Unreacted Small Reagents & Salts ($MW < 150\text{ Da}$): Freely permeate with $R < 10\%$.
• Homogeneous Catalysts (e.g. Grubbs, BINAP, Rh complexes): Retained with $R > 99.0\%$ for direct reuse.

# 2. Permeate Flux Modeling: The Solution-Diffusion & Osmotic Model

Unlike aqueous filtration where viscosity is constant, organic solvent flux varies dramatically depending on solvent viscosity ($\mu_s$) and membrane swelling.

# 2.1. Spiegler-Kedem Transport Equation

The volumetric solvent flux ($J_v$ in $\text{L}/(\text{m}^2\cdot\text{h})$) is:

Where:

• $\Delta P = \frac{P_{in} + P_{out}}{2} - P_{perm}$: Transmembrane pressure ($TMP$).
• $\Delta \pi = i \cdot \Delta C \cdot R_g \cdot T$: Van 't Hoff osmotic back-pressure generated by concentrated API molecules.
• $\mu_{solvent}$: Dynamic solvent viscosity ($\text{mPa}\cdot\text{s}$).
• $R_m$: Intrinsic clean membrane hydraulic resistance ($\text{m}^{-1}$).
• $R_{cp}$: Resistance from concentration polarization.

# 2.2. Concentration Polarization ($CP$)

Under cross-flow conditions, rejected API molecules build up at the membrane wall:

Where the mass transfer boundary layer coefficient is:

To prevent osmotic stalling and severe flux decline, the cross-flow circulation velocity along the membrane face must exceed $1.0 \text{ to } 2.5\text{ m/s}$.

# 3. Non-Thermal Constant-Volume Diafiltration (Solvent Swap)

Instead of boiling off solvent A and charging solvent B in repeated batch vacuum distillation cycles, OSN accomplishes Constant-Volume Diafiltration:

flowchart LR
    A["Solvent B Addition Tank"] -->|Q_add = Q_perm| B["API Retentate Vessel (Solvent A + B)"]
    B --> C["High-Pressure Booster Pump (35 bar)"]
    C --> D["OSN Cross-Flow Membrane Skid"]
    D -->|Permeate: Pure Solvent A| E["Solvent A Recovery Tank"]
    D -->|Retentate: Concentrated API| B

    style A fill:#e0f2fe,stroke:#0284c7
    style B fill:#fef3c7,stroke:#d97706
    style C fill:#a855f7,stroke:#7e22ce
    style D fill:#10b981,stroke:#047857
    style E fill:#fee2e2,stroke:#dc2626

# 3.1. Mathematical Wash Curve

The residual concentration of initial Solvent A ($C_A$) as a function of Diafiltration Volumes ($D = V_{permeate} / V_{system}$) is:

To replace $>99.0\%$ of original solvent A requires:

# 4. Comprehensive Worked Industrial Case Study: 500 L API Solvent Exchange

# Problem Statement:

An oncology intermediate ($MW = 550\text{ g/mol}$) is synthesized in $500\text{ Liters}$ of Tetrahydrofuran (THF). It must be exchanged into Ethanol (EtOH) for crystallization (residual $\text{THF} < 0.5\text{ wt}\%$).

• Initial solution: $500\text{ L}$ ($50\text{ g/L API}$, Total $M_{API} = 25\text{ kg}$).
• Membrane selected: Crosslinked Polyimide (P84) spiral-wound element ($MWCO = 300\text{ Da}$, $R_{API} = 99.8\%$).
• Operating pressure: $TMP = 35\text{ bar}$.
• Operating temperature: $25^\circ\text{C}$.
• Experimentally measured flux in THF/EtOH mixture: $J_v = 25\text{ L}/(\text{m}^2\cdot\text{h})$.
• Target process duration: $\tau \le 4.0\text{ hours}$.

# Step 1: Calculate Total Permeate Volume

• For $99.5\%$ solvent replacement:

• Total permeate volume to pass through the membrane:

# Step 2: Determine Required Membrane Surface Area

• Required average permeate flow rate:

• Required active membrane surface area:

• Selecting standard 8-inch $\times$ 40-inch spiral-wound modules (approx $28.0\text{ m}^2$ active area per element):
  • A single 8040 module housing provides $28.0\text{ m}^2$, exceeding the requirement with $+5.6\%$ design margin.

# Step 3: Energy Savings Comparison vs. Vacuum Distillation

• Thermal Vacuum Distillation:
  • Evaporating $2,650\text{ L}$ of THF ($\Delta H_{vap} = 410\text{ kJ/kg}$, $\rho = 0.889\text{ kg/L}$):

• Plus cooling tower / chiller condenser load of another $280\text{ kWh}$.
• OSN Membrane Skid:
  • High-pressure booster pump hydraulic power ($Q = 3.0\text{ m}^3/\text{h}$ cross-flow, $\Delta P = 35\text{ bar}$):

• Energy consumed over $4.0\text{ hours}$: $4.49\text{ kW} \cdot 4\text{ h} = \mathbf{18.0\text{ kWh electrical energy}}$.
• Net Energy Savings: $> 93\%$ reduction in total plant utility consumption!

# 5. Membrane Materials Matrix & Chemical Compatibility

# Applicable Engineering Standards & Codes Used

• ASME BPE: Hygienic Membrane Housings and Tri-Clamp Process Skids.
• ASTM D3864: Standard Guide for Continual On-Line Monitoring Systems.
• ISPE Good Practice Guide: Membrane Systems in Pharmaceutical Applications.
• FDA 21 CFR Part 211.65: Equipment Construction (Extractables and Leachables validation for polymeric membranes).